Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 32Metastatic Castration-resistant Prostate Cancer 3Prostatic Diseases 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Urogenital Neoplasms 1Thrombocytopenia 1Prostatic Neoplasms, Castration-Resistant 1Prostate Cancer Metastatic 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Metastatic Hormone Naive Prostate Cancer 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Liver Neoplasms 1High-Risk Localized Prostate Cancer 1Glioma 1Glioblastoma 1Genital Neoplasms, Male 1Genital Diseases, Male 1Disease 1Cytopenia 1Carcinoma, Hepatocellular 1Carcinoma 1Astrocytoma 1Anemia 1

Interventions

padeliporfin 4palladium-bacteriopheophorbide 1ixabepilone 1enzalutamide 1darolutamide 1apalutamide 1Therapeutics 1Standard of Care 1Radiotherapy 1Prednisone 1Pluvicto 1Docetaxel 1Androgen Antagonists 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Genital Diseases, Male × Pluvicto × Clear all
NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

UNICANCER

Phase 3 Recruiting
500 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡